Summit Therapeutics
SMMT
SMMT
228 hedge funds and large institutions have $2.12B invested in Summit Therapeutics in 2025 Q3 according to their latest regulatory filings, with 41 funds opening new positions, 79 increasing their positions, 69 reducing their positions, and 44 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding in top 10
Funds holding in top 10: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
0.67% more ownership
Funds ownership: 13.18% → 13.85% (+0.67%)
7% less first-time investments, than exits
New positions opened: 41 | Existing positions closed: 44
4% less funds holding
Funds holding: 237 → 228 (-9)
Holders
228
Holding in Top 10
5
Calls
$115M
Puts
$91.1M
Top Buyers
| 1 | +$55.9M | |
| 2 | +$48.4M | |
| 3 | +$26.5M | |
| 4 |
Nomura Holdings
Tokyo,
Japan
|
+$20.8M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$13.1M |
Top Sellers
| 1 | -$16.8M | |
| 2 | -$11.7M | |
| 3 | -$9M | |
| 4 |
Charles Schwab
San Francisco,
California
|
-$8.58M |
| 5 |
RT
Rockland Trust
Hanover,
Massachusetts
|
-$8.51M |
